123 related articles for article (PubMed ID: 35986570)
1. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Wang Y; Ma Z; An Z; Zhang Y; Feng X; Yu X
Cancer Med; 2023 Feb; 12(3):2227-2237. PubMed ID: 35986570
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.
Jfri A; Meltzer R; Mostaghimi A; LeBoeuf N; Guggina L
JAMA Oncol; 2022 Oct; 8(11):1635-43. PubMed ID: 36227613
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.
Shan W; Wu G; Huang Y; Zeng H; Xia W; Lin Z; Xu B
Ann Hematol; 2022 Aug; 101(8):1741-1753. PubMed ID: 35688904
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis.
Zhang Y; Ma Z; Wang Y; Feng X; An Z
Expert Rev Clin Pharmacol; 2023; 16(9):855-863. PubMed ID: 37489925
[TBL] [Abstract][Full Text] [Related]
6. Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Li J; Gu J
J Clin Pharmacol; 2019 Jan; 59(1):45-54. PubMed ID: 30088662
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Wen Y; Meng L; Zhang X; Gao Q
Expert Rev Hematol; 2022 Sep; 15(9):849-856. PubMed ID: 35920616
[TBL] [Abstract][Full Text] [Related]
9. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
10. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y; Lacouture ME; Su X; Wu S
J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
[TBL] [Abstract][Full Text] [Related]
11. Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Yang W; Li S; Yang Q
Medicine (Baltimore); 2019 May; 98(20):e15731. PubMed ID: 31096532
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Raphael J; Desautels D; Pritchard KI; Petkova E; Shah PS
Eur J Cancer; 2018 Mar; 91():38-46. PubMed ID: 29331750
[TBL] [Abstract][Full Text] [Related]
15. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
16. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Zhang Y; La B; Liang B; Gu Y
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833153
[TBL] [Abstract][Full Text] [Related]
17. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
18. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
20. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Zhang Y; Ma Z; Sun X; Feng X; An Z
Breast; 2022 Apr; 62():162-169. PubMed ID: 35219113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]